171 related articles for article (PubMed ID: 11513188)
21. Resolution of refractory ascites after transcoronary septal ablation for hypertrophic obstructive cardiomyopathy in a cirrhotic patient.
Höblinger A; Tiemann K; Nickenig G; Sauerbruch T; Lammert F
Z Gastroenterol; 2008 Oct; 46(10):1194-7. PubMed ID: 18937189
[TBL] [Abstract][Full Text] [Related]
22. Correlation between portal/hepatic vein gradient and response to transjugular intrahepatic portosystemic shunt creation in refractory ascites.
Nair S; Singh R; Yoselewitz M
J Vasc Interv Radiol; 2004 Dec; 15(12):1431-4. PubMed ID: 15590801
[TBL] [Abstract][Full Text] [Related]
23. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
Colombato L
J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
[TBL] [Abstract][Full Text] [Related]
24. Transjugular intrahepatic portosystemic shunt migration in patients undergoing liver transplantation.
Khan TT; Reddy KS; Johnston TD; Lo FK; Shedlofsky S; Grubb S; Ranjan D
Int Surg; 2002; 87(4):279-81. PubMed ID: 12575815
[TBL] [Abstract][Full Text] [Related]
25. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
26. Abnormal plasma peptide YY(3-36) levels in patients with liver cirrhosis.
Valentini L; Schuetz T; Omar A; Gläser S; Kasim E; Nowotny P; Kroencke T; Ockenga J
Nutrition; 2011 Sep; 27(9):880-4. PubMed ID: 21819934
[TBL] [Abstract][Full Text] [Related]
27. Transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis and concomitant portal vein thrombosis.
Van Ha TG; Hodge J; Funaki B; Lorenz J; Rosenblum J; Straus C; Leef J
Cardiovasc Intervent Radiol; 2006; 29(5):785-90. PubMed ID: 16850140
[TBL] [Abstract][Full Text] [Related]
28. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.
Albillos A; Bañares R; González M; Catalina MV; Molinero LM
J Hepatol; 2005 Dec; 43(6):990-6. PubMed ID: 16139922
[TBL] [Abstract][Full Text] [Related]
29. Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites.
Wong F; Bomzon A; Allard J; Liu P; Blendis L
Clin Sci (Lond); 1999 May; 96(5):467-74. PubMed ID: 10209078
[TBL] [Abstract][Full Text] [Related]
30. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites.
Salerno F; Merli M; Riggio O; Cazzaniga M; Valeriano V; Pozzi M; Nicolini A; Salvatori F
Hepatology; 2004 Sep; 40(3):629-35. PubMed ID: 15349901
[TBL] [Abstract][Full Text] [Related]
31. Transjugular intrahepatic portosystemic shunts in liver transplant recipients.
Kim JJ; Dasika NL; Yu E; Fontana RJ
Liver Int; 2008 Feb; 28(2):240-8. PubMed ID: 18251981
[TBL] [Abstract][Full Text] [Related]
32. Cirrhotic patients with a transjugular intrahepatic portosystemic shunt undergoing major extrahepatic surgery.
Kim JJ; Dasika NL; Yu E; Fontana RJ
J Clin Gastroenterol; 2009 Jul; 43(6):574-9. PubMed ID: 19169145
[TBL] [Abstract][Full Text] [Related]
33. Incarceration of umbilical hernia following transjugular intrahepatic portosystemic shunt for the treatment of ascites.
Trotter JF; Suhocki PV
Liver Transpl Surg; 1999 May; 5(3):209-10. PubMed ID: 10226112
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with body-fat changes in prevalent peritoneal dialysis patients.
Vasselai P; Kamimura MA; Bazanelli AP; Pupim LB; Avesani CM; da Mota Ribeiro FS; Manfredi SR; Draibe SA; Cuppari L
J Ren Nutr; 2008 Jul; 18(4):363-9. PubMed ID: 18558301
[TBL] [Abstract][Full Text] [Related]
35. Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents.
Barrio J; Ripoll C; Bañares R; Echenagusia A; Catalina MV; Camúñez F; Simó G; Santos L
Eur J Radiol; 2005 Jul; 55(1):120-4. PubMed ID: 15950109
[TBL] [Abstract][Full Text] [Related]
36. Prognosis assessment of cirrhotic patients with refractory ascites treated with a peritoneovenous shunt.
Guardiola J; Xiol X; Escribá JM; Castellví JM; Castellote J; Baliellas C; Rafecas A; Casais LA
Am J Gastroenterol; 1995 Dec; 90(12):2097-102. PubMed ID: 8540495
[TBL] [Abstract][Full Text] [Related]
37. Survival benefit of TIPS versus serial paracentesis in patients with refractory ascites: a single institution case-control propensity score analysis.
Gaba RC; Parvinian A; Casadaban LC; Couture PM; Zivin SP; Lakhoo J; Minocha J; Ray CE; Knuttinen MG; Bui JT
Clin Radiol; 2015 May; 70(5):e51-7. PubMed ID: 25758602
[TBL] [Abstract][Full Text] [Related]
38. Transjugular intrahepatic portosystemic shunts in hemodialysis-dependent patients and patients with advanced renal insufficiency: safety, caution, and encephalopathy.
Haskal ZJ; Radhakrishnan J
J Vasc Interv Radiol; 2008 Apr; 19(4):516-20. PubMed ID: 18375295
[TBL] [Abstract][Full Text] [Related]
39. Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt.
Russo MW; Jacques PF; Mauro M; Odell P; Brown RS
Liver Transpl; 2002 Mar; 8(3):271-7. PubMed ID: 11910573
[TBL] [Abstract][Full Text] [Related]
40. Pros and cons of TIPS for refractory ascites.
Sanyal AJ
J Hepatol; 2005 Dec; 43(6):924-5. PubMed ID: 16246451
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
